| scholarly article | Q13442814 |
| P50 | author | Bruce E. Sands | Q29922058 |
| Paul Rutgeerts | Q30247987 | ||
| Seymour Katz | Q57113097 | ||
| Brian G. Feagan | Q64364618 | ||
| Charles N Bernstein | Q88613774 | ||
| Walter Reinisch | Q95337727 | ||
| P2093 | author name string | István Altorjay | |
| István Rácz | |||
| László Simon | |||
| László Bene | |||
| Daniel Hommes | |||
| Antoine Cortot | |||
| Dennis Riff | |||
| May Cheng | |||
| Michael Gaspari | |||
| Tillman Pearce | |||
| Williem de Villiers | |||
| P2860 | cites work | A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease | Q24680126 |
| Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease | Q35760634 | ||
| Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy | Q40528442 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Crohn's disease | Q1472 |
| placebo | Q269829 | ||
| P304 | page(s) | 233-42 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Inflammatory Bowel Diseases | Q15749161 |
| P1476 | title | Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study | |
| P478 | volume | 16 |
| Q57100268 | A model of TH17-associated ileal hyperplasia that requires both IL-17A and IFNγ to generate self-tolerance and prevent colitis |
| Q38126789 | Advances in the treatment of coeliac disease: an immunopathogenic perspective |
| Q38262453 | Biologic treatment in Sjögren's syndrome. |
| Q57162305 | Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions |
| Q37076943 | CD4(+) T-cell subsets in intestinal inflammation |
| Q58235912 | CD8 T Cells and IFN-γ Emerge as Critical Players for Psoriasis in a Novel Model of Mouse Psoriasiform Skin Inflammation |
| Q38184586 | Celiac disease: the search for adjunctive or alternative therapies |
| Q36389114 | Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo |
| Q35885793 | Coeliac Disease - New Pathophysiological Findings and Their Implications for Therapy |
| Q34883210 | Current and emerging drugs for the treatment of inflammatory bowel disease |
| Q63976730 | Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy |
| Q38068963 | Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update |
| Q36818290 | Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases |
| Q37952792 | Cytokine blockade in inflammatory bowel diseases |
| Q39206254 | Cytokines in inflammatory bowel disease |
| Q37909490 | Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases |
| Q92447462 | Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD |
| Q34563301 | Distinct profiles of effector cytokines mark the different phases of Crohn's disease |
| Q49205651 | Divergent Roles of Interferon-γ and Innate Lymphoid Cells in Innate and Adaptive Immune Cell-Mediated Intestinal Inflammation. |
| Q64102310 | Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis |
| Q39881787 | Emerging drugs to treat Crohn's disease |
| Q47719552 | Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. |
| Q38741014 | Enrichment of IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets is associated with reduction of NKp44+ ILC3s in the terminal ileum of Crohn's disease patients. |
| Q41017055 | Epitope Mapping of Neutralizing Monoclonal Antibodies to Human Interferon-γ Using Human-Bovine Interferon-γ Chimeras |
| Q47350920 | Familial Association of Granulocyte-Macrophage Colony Stimulating Factor Autoantibodies in Inflammatory Bowel Disease. |
| Q91810029 | Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13 |
| Q37687874 | Future biologic targets for IBD: potentials and pitfalls |
| Q90364641 | IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption |
| Q93381993 | IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting |
| Q38902578 | Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair |
| Q39062398 | Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis. |
| Q26785537 | Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments |
| Q82318199 | Inside the microbial and immune labyrinth: totally gutted |
| Q43116514 | Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo |
| Q37603372 | Interferon-γ and systemic autoimmunity |
| Q55429416 | Interferons in Traumatic Brain and Spinal Cord Injury: Current Evidence for Translational Application. |
| Q64078046 | Intestinal Organoids as a Novel Complementary Model to Dissect Inflammatory Bowel Disease |
| Q37788217 | Investigational agents for Crohn's disease |
| Q37773243 | Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer |
| Q38805575 | Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases |
| Q34046139 | Medical management of Crohn's disease. |
| Q35034672 | Modulation of interferon activity-associated soluble molecules by appendicitis and appendectomy limits colitis-identification of novel anti-colitic targets |
| Q36341390 | NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine |
| Q37194982 | Neuroprotective intervention by interferon-γ blockade prevents CD8+ T cell-mediated dendrite and synapse loss |
| Q35003977 | New targets for mucosal healing and therapy in inflammatory bowel diseases |
| Q38253844 | Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease |
| Q34170574 | Novel therapies for coeliac disease |
| Q48351328 | Old and New Lymphocyte Players in Inflammatory Bowel Disease |
| Q35659341 | Pathogenesis of Crohn's disease |
| Q38750548 | Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. |
| Q38665573 | Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders |
| Q38593257 | Pathway-based approaches to the treatment of inflammatory bowel disease |
| Q37896092 | Pharmacotherapy and management strategies for coeliac disease. |
| Q50072080 | Potential immunotherapies for sarcoidosis |
| Q37847059 | Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases |
| Q35012024 | Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation |
| Q38038684 | Recent advances in the development of new treatments for celiac disease |
| Q46244253 | Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases |
| Q27026918 | Support for patients with celiac disease: A literature review |
| Q39121473 | Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. |
| Q38138195 | Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad. |
| Q37813138 | Th17-cytokine blockers as a new approach for treating inflammatory bowel disease |
| Q34074137 | Th17-related cytokines: new players in the control of chronic intestinal inflammation |
| Q92276623 | The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease |
| Q64897993 | The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review. |
| Q55222890 | The Role of T-Cell Subsets in Chronic Inflammation in Celiac Disease and Inflammatory Bowel Disease Patients: More Common Mechanisms or More Differences? |
| Q38016781 | The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet |
| Q36518480 | The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. |
| Q38478216 | The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD. |
| Q38132555 | The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. |
| Q26825413 | Therapeutic approaches for celiac disease |
| Q38177338 | Translational research and efficacy of biologics in Crohn's disease: a cautionary tale |
| Q36057492 | Trial Watch: Immunostimulatory cytokines |
| Q38744710 | Type 1 Interferon in the Human Intestine-A Co-ordinator of the Immune Response to the Microbiota. |
| Q53638799 | [Effector T cells]. |
Search more.